G35
Conditions
Interventions
Group 1: Patients who are treated with fampridine during routine clinical treatment take part in an electronic walking test prior to and following fampridine administration. During this walking test,
Sponsors
Biogen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Clinical indication for a therapy with Fampridine according to german SmPC
Exclusion criteria
Exclusion criteria: Contra- indication for a therapy with Fampridine according to german SmPC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients who are treated with fampridine during routine clinical treatment take part in an electronic walking test prior to and following fampridine administration. During this walking test, patients walk back and forth a distance of 25-ft for a maximal period of six minutes. Primary Endpoint: Walking distance covered on the walking test, prior to and during treatment with fampridine. Respective measurements occur during routine clinical treatement on a quarterly (year) basis. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Endpoint: Speed during the covering of curves in the 25-ft walk. Additionally: Measurement of Fatigue by means of the self-report measure "Würzburger Erschöpfungsinventar bei Multipler Sklerose (WEIMUS), administered on the same occasions during which the walking test is implemented. | — |
Countries
Germany
Contacts
Public ContactPatrick Oschmann
Klinikum Bayreuth GmbH, Department of Neurology
Outcome results
None listed